A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
Inclusion Criteria:
Exclusion Criteria:
Saint Louis Park, Minnesota 55416, United States
Bordeaux, 33000, France
Dijon, 21000, France
Bear Sheva, Israel
BEER Yaaqov, 70300, Israel
Jerusalem, 91120, Israel
Roma, 00161, Italy
Fukuyama-shi, 720-0001, Japan
Kashiwa-shi, 277-8577, Japan
Kitakyushu-shi, 807-8556, Japan
Osakasayama-shi, 589-8511, Japan
Suita-shi, 565-0871, Japan
L'Hospitalet de Llobregat, 08908, Spain